
Rivipansel sodium
CAS No. 1189037-60-2
Rivipansel sodium( GMI-1070 | PF-06460031 )
Catalog No. M10649 CAS No. 1189037-60-2
Rivipansel sodium (GMI-1070, PF-06460031)?is a novel small molecule glycomimetic pan-Selectin antagonist with IC50 of 4.3 uM, 423 uM and 337 uM for E-selectin, P-selectin and L-selectin, respectively.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 873 | Get Quote |
![]() ![]() |
50MG | 1782 | Get Quote |
![]() ![]() |
100MG | 2250 | Get Quote |
![]() ![]() |
200MG | Get Quote | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameRivipansel sodium
-
NoteResearch use only, not for human use.
-
Brief DescriptionRivipansel sodium (GMI-1070, PF-06460031)?is a novel small molecule glycomimetic pan-Selectin antagonist with IC50 of 4.3 uM, 423 uM and 337 uM for E-selectin, P-selectin and L-selectin, respectively.
-
DescriptionRivipansel sodium (GMI-1070, PF-06460031)?is a novel small molecule glycomimetic pan-Selectin antagonist with IC50 of 4.3 uM, 423 uM and 337 uM for E-selectin, P-selectin and L-selectin, respectively; predominantly inhibits E-selectin-mediated adhesion and dramatically inhibits sRBC-leukocyte interactions, leading to improved microcirculatory blood flow and improved survival; a valuable novel therapeutic intervention for acute sickle cell crises.Anemia Phase 3 Clinical.
-
In Vitro——
-
In Vivo——
-
SynonymsGMI-1070 | PF-06460031
-
PathwayCytoskeleton/Cell Adhesion Molecules
-
TargetSelectin
-
RecptorSelectin
-
Research AreaOther Indications
-
IndicationAnemia
Chemical Information
-
CAS Number1189037-60-2
-
Formula Weight——
-
Molecular FormulaC58H74N6O31S3
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCC1C(C(C(C(O1)OC2C(CC(CC2OC3C(C(C(C(O3)CO)O)OC(CC4CCCCC4)C(=O)[O-])OC(=O)C5=CC=CC=C5)C(=O)NCCNC(=O)COCCOCC(=O)NC6=C7C(=CC(=C6)S(=O)(=O)[O-])C=C(C=C7S(=O)(=O)[O-])S(=O)(=O)[O-])NC(=O)C8=CC(=O)NC(=O)N8)O)O)O.[Na+].[Na+].[Na+].[Na+]
-
Chemical Name(S)-2-(((2R,3R,4S,5S,6R)-3-(benzoyloxy)-2-(((1R,2R,3S,5R)-3-(2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxamido)-5-((2-(2-(2-(2-oxo-2-((3,6,8-trisulfonaphthalen-1-yl)amino)ethoxy)ethoxy)acetamido)ethyl)carbamoyl)-2-(((2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)cyclohexyl)oxy)-5-hydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)oxy)-3-cyclohexylpropanoic acid
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Chang J, et al. Blood. 2010 Sep 9;116(10):1779-86.
2. Azab AK, et al. Blood. 2012 Feb 9;119(6):1468-78.
3. Wun T, et al. PLoS One. 2014 Jul 2;9(7):e101301.
molnova catalog



related products
-
HMCEF
A novel P-selectin inhibitor that directly binds to P-selectin.
-
GMI-1271
A novel specific glycomimetic E-Selectin antagonist with Kd of 0.46 uM, IC50 of 1.75 uM.
-
PSI-421
A potent, orally bioavailable P-selectin inhibitor with improved pharmacokinetic properties and oral efficacy in models of vascular injury.